, and for PhGl vs pain -60.8;23.0 [-18.9]. Conclusions: In patients with PsA, PaGl was in general scored considerably higher than PhGl. The two scores were poorly connected not only on the individual level but also on group level with no systematic differences between the scores. PaGl was best predicted by pain, and PhGl by SCJ reflecting patients and physicians diverging attitudes to the importance of the different disease manifestations. 
Methods: The findings of the FUTURE 2 trial through Wk 104 have been previously reported. 3 Post-hoc shift analyses were performed on ACR response between Wks 24 and 104 for subgroups of secukinumab-treated pts, based on their higher response rate at an earlier time point in 1 out of 4 categories (ACR non-responders [NR], ACR20, 50 or 70) by evaluating whether the response improved, sustained or worsened at a later time point using exclusive categories and as observed analyses. Similar shift analysis on DAS28-CRP derived criteria were performed in 4 exclusive categories extrapolated from rheumatoid arthritis: high, moderate, low disease activity (HDA, MDA, LDA) or remission (REM) only.
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Results: In total, 86/100 (86%) and 76/100 (76%) pts in the secukinumab 300 and 150mg groups, respectively, completed the 104-wk treatment. Of which, 73/70 and 81/75 pts in secukinumab 300/150mg were eligible for ACR and DAS28-CRP shift analysis, respectively, from Wk 24 to 104. Baseline demographics and clinical characteristics were balanced across the two dose groups. 
Conclusions:
In this post-hoc analysis, a majority of secukinumab-treated pts who achieved at least ACR20 and PASI 75 response or at least MDA at Wk 24 sustained or improved their ACR and PASI responses or sustained or reduced their disease status at Wk 104. Numerically higher sustained response and LDA or REM rate was observed for secukinumab 300mg, thereby extending the sustainability of response and lowering the disease activity that has been previously reported at group level. 2, 3 
